Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179
Recruiting
The purpose of this Phase 2b study is to evaluate the safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
05/21/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts +6 locations
Conditions: Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Register for Updates
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693
Recruiting
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia +47 locations
Conditions: Breast Cancer
Register for Updates
Effect of Snacks on Aging
NCT06879626
Recruiting
The purpose of this study is to determine if daily consumption of 2 oz of pecans compared to 3.5 oz pretzel snacks for 12 weeks will 1) contribute to the body's ability to protect itself from oxidative damage (caused by oxygen radicals created by ultraviolet (UV) B light) by evaluating skin resistance to UV light irritation, skin fats/oils degradation and "rusting", and oxidative damage to the skin genes; and 2) explore the mechanisms of how snack consumption may affect aging by analyzing blood... Read More
Gender:
FEMALE
Ages:
Between 55 years and 75 years
Trial Updated:
05/21/2025
Locations: UCLA Center for Human Nutrition, Los Angeles, California
Conditions: Aging
Register for Updates
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276
Recruiting
The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Healthy, Hepatic Impairment
Register for Updates
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
NCT00807482
Recruiting
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predispo... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/21/2025
Locations: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Kartagener Syndrome
Register for Updates
C.A.P.A.B.L.E. (Cross-Training and Physical Activity: A Better Life Experience Study)
NCT03750981
Recruiting
This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Cancer Survivors
Register for Updates
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT04741997
Recruiting
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Register for Updates
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934
Recruiting
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: GSK Investigational Site, Denver, Colorado +82 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
NCT05753306
Recruiting
This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Register for Updates
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: OM Research LLC, Lancaster, California +59 locations
Conditions: Primary Biliary Cholangitis
Register for Updates
Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders
NCT06274164
Recruiting
Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment studies. Biomarkers are measures of what is happening inside the body, shown by the results of laboratory, imaging or other tests. Biomarkers can help doctors and scientists diagnose diseases and health... Read More
Gender:
ALL
Ages:
Between 1 month and 80 years
Trial Updated:
05/21/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: RAI1 Gene 17P11.2 Deletion+Duplication
Register for Updates
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +161 locations
Conditions: Endometrial Cancer
Register for Updates